Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple myeloma. Onyx Pharmaceuticals has previously announced its intent to acquire Proteolix Inc. Until the transaction closes, carfilzomib remains an asset of Proteolix Inc.
"The breadth of data being presented at ASH showcases our growing, diverse oncology pipeline, which we expect to fuel the future growth of Onyx, and positions the company to bring multiple, new treatment options to cancer patients," said Todd Yancey, vice president clinical development at Onyx. "Despite recent treatment advances, multiple myeloma remains a disease with poor long-term survival and there is a tremendous need for new therapies. Assuming the Proteolix transaction closes, our development plan will include evaluating carfilzomib, a next-generation selective proteasome inhibitor, across multiple lines of therapy, as a single agent and in combination with other therapies for the treatment of multiple myeloma."
Carfilzomib data highlights include:
Multiple Myeloma